It is the first test the FDA has cleared for use in symptomatic adults aged 40 and over, according to C2N Diagnostics.

Adults aged 40 years and older with symptoms of cognitive impairment may now qualify for a recently approved blood test for Alzheimer disease.

Will getting a blood test for amyloid levels eventually form part of routine primary care health checks, or are we putting ...

The FDA has cleared PrecivityAD2, a single blood test designed to help health care professionals rule in or rule out an Alzheimer’s disease diagnosis, according to a press release from the test’s ...

The US Food and Drug Administration has cleared Roche and partner Eli Lilly’s blood test to help ​identify signs of Alzheimer ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...

A new FDA-cleared blood test could make Alzheimer’s assessment less invasive for adults aged 40 and older who have signs of ...

C2N Diagnostics receives US FDA nod for PrecivityAD2 test, a first Alzheimer’s blood test for adults with cognitive symptoms as young as 40: St. Louis Monday, August 24, 2026, 1 ...

The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new ...

PrecivityAD2 is the first blood-based biomarker for people as young as 40 with cognitive s ...